Analysis of PALB2/FANCN-associated breast cancer families
about
Structural basis for recruitment of BRCA2 by PALB2PALB2 is an integral component of the BRCA complex required for homologous recombination repairPALB2 regulates recombinational repair through chromatin association and oligomerizationBreast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repairDICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumorsHomologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteinsUnraveling the mechanism of BRCA2 in homologous recombinationPALB2: the hub of a network of tumor suppressors involved in DNA damage responsesCellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insightsMitotic homologous recombination maintains genomic stability and suppresses tumorigenesisFanconi anaemia and the repair of Watson and Crick DNA crosslinksCooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombinationLoss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppressionPalb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancerNovel germline PALB2 truncating mutations in African American breast cancer patientsRare germline mutations in PALB2 and breast cancer risk: a population-based study.Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer familiesCancer incidence in relatives of British Fanconi Anaemia patients.Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.A novel germline PALB2 deletion in Polish breast and ovarian cancer patientsCancer-causing mutations in the tumor suppressor PALB2 reveal a novel cancer mechanism using a hidden nuclear export signal in the WD40 repeat motifPALB2 variants in hereditary and unselected Finnish prostate cancer cases.Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.FANCM of the Fanconi anemia core complex is required for both monoubiquitination and DNA repair.Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutationsPALB2/FANCN: recombining cancer and Fanconi anemia.Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada.Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations.Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.Mutations in BRCA2 and PALB2 in male breast cancer cases from the United StatesIdentification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian womenPrevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore.Association of PALB2 sequence variants with the risk of familial and early-onset breast cancer in a South-American populationGrowing recognition of the role for rare missense substitutions in breast cancer susceptibilityThe ups and downs of DNA repair biomarkers for PARP inhibitor therapiesGerm-line and somatic DICER1 mutations in pineoblastoma.Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast CancersInitial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
P2860
Q24315745-CBB5AA7B-B443-418C-AC56-E2A3B16B9905Q24316113-9992D715-38DD-4B8F-9898-26ABBB486396Q24322952-5611A61C-9C02-4B3F-98DC-0A5DD9D1D400Q24338777-E7BA8E2C-32C6-48BF-A072-EDDD31E709B4Q24629110-B237D579-D48F-46A7-B8BE-35EF57A56D7AQ28085364-806BFACA-77BB-41B3-8E71-F895552F0705Q28242443-BA72F3BF-0899-4BC4-940B-E73BF61AEE28Q28243398-F051860C-15B3-4F0D-94AC-23B1A1570FE4Q28252640-ECAC79B2-A725-4B9C-943A-C34F9CE4F2AFQ28274000-24A20DF5-62EE-42AE-879C-F12A5E45AB1BQ28283549-788686CC-C13D-4106-80EC-79196BCF6581Q28294199-76299386-0134-47A2-9ABE-FE8E3C68FAB6Q28512158-4624AE6A-95CC-4343-8953-1B4787DC6788Q28586302-27986B73-0FDE-4182-B361-EA6F1A8BE015Q28741002-BC2F065B-6F5C-497B-9E9A-2D0A58C921DEQ30417260-B0D50A70-796C-47CA-8377-51B8DC1DA591Q30448232-D4DA8759-3DC6-4F44-A344-64D455490D75Q33337514-3E1BBC9D-8F54-4AE9-BE6A-9668A4AE16D8Q33368870-1C1796AA-F96E-4F15-9311-40B6329EC35AQ33429801-D63615D1-8533-4CAF-9A6C-666B51914AF9Q33528298-90A7CE8B-C3FA-467B-82B3-3DDD57945772Q33558127-9EB3A09D-52C7-483E-81A4-F309BD83D959Q33590262-41EB70AD-94E3-4D9D-945F-C151537B1BDAQ33810128-7EFB892F-F700-4D93-A536-382F54050A85Q33985910-69A9AC7C-8FCA-4FB8-87BA-53D60749AF19Q34030921-4AB5FFC7-4F43-4EAF-8B86-C551A2A498A3Q34168415-4F8D590B-B4DD-4D31-9DB1-5E1DE2EC630EQ34178875-6A456AE1-6139-40B4-BAD0-6BFC72E4AE31Q34460831-2BAECE1B-840C-4A12-B877-409229025AA5Q34532927-45ACBA04-C14E-4B51-86A9-DB7FE922D49BQ34542998-509FF6D8-3F53-4603-9E6C-D2C73AB60E41Q34687498-9E1ADEE7-582E-4FDB-ADCE-DC5A3C245A51Q34720527-84015213-9398-4C99-8B2A-FA051C7A5276Q34974233-31359079-87AC-4A62-B9F2-4EB0C2573779Q35068734-7E6DFCB1-0D3E-4854-9775-102E9FA8EEC3Q35106767-955B2E8F-7057-4890-B756-D3E47D02E3F3Q35232277-3EB787F5-58E9-4F3D-BC88-987DA47E1DB7Q35240049-130719A6-6D1E-4639-A54B-4617E57DE8C2Q35665705-22B52327-837A-4DDC-B99E-202E08FCC681Q35684995-5F50CC1F-84F0-452A-A9E0-6DC8ED690113
P2860
Analysis of PALB2/FANCN-associated breast cancer families
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Analysis of PALB2/FANCN-associated breast cancer families
@ast
Analysis of PALB2/FANCN-associated breast cancer families
@en
Analysis of PALB2/FANCN-associated breast cancer families
@nl
type
label
Analysis of PALB2/FANCN-associated breast cancer families
@ast
Analysis of PALB2/FANCN-associated breast cancer families
@en
Analysis of PALB2/FANCN-associated breast cancer families
@nl
prefLabel
Analysis of PALB2/FANCN-associated breast cancer families
@ast
Analysis of PALB2/FANCN-associated breast cancer families
@en
Analysis of PALB2/FANCN-associated breast cancer families
@nl
P2093
P2860
P50
P356
P1476
Analysis of PALB2/FANCN-associated breast cancer families
@en
P2093
Aletta Poll
Atilla Omeroglu
David M Livingston
Erik H van Beers
Louise A Quenneville
Marc Tischkowitz
Nancy Hamel
P2860
P304
P356
10.1073/PNAS.0701724104
P407
P577
2007-04-17T00:00:00Z